Immunic gets a "positive surprise" from lead asset trialApril 13, 2023 at 08:00 AM EDT
Immunic Inc (NASDAQ: IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC). Vitt describes it as "wonderful data" that came as a "positive surprise." Contact DetailsProactive United States Proactive United States +1 347-449-0879 More NewsView More
2 Ways to Trade Qualcomm Ahead of November’s Earnings
Today 18:35 EDT
Lululemon: 2 Signs the Bottom Is In, and 1 Sign It Isn’t
Today 17:44 EDT
Got 1K to Invest? These 3 Stocks Are Still Attractive Buys
Today 16:26 EDT
Why Micron Stock Could Soar 35% on AI Memory Demand
Today 15:12 EDT
5 Reasons Coca-Cola Stock Will Hit New Highs This Year
Today 14:47 EDT
Recent QuotesView More
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes. By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
|
| ||||||
